Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296023 · ClinicalTrials.gov registry record · NA
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00296023 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants.
The verdict
NCT00296023, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and methotrexate and tacrolimus after the transplant may stop this from happening. PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant in treating older or frail patients with hematologic cancer.
Interventions
- DRUG fludarabine phosphate
- BIOLOGICAL filgrastim
- DRUG busulfan
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL therapeutic allogeneic lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1999-01 |
| Est. Completion | 2008-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296023
The ClinicalTrials.gov registry entry for NCT00296023 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fludarabine phosphate is the first listed.
NCT00296023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00296023 about?
NCT00296023 is a clinical study titled "Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer". RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replac...
What is the current status of trial NCT00296023?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 1999-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00296023?
The interventions under investigation include: fludarabine phosphate (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG), anti-thymocyte globulin (BIOLOGICAL), therapeutic allogeneic lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00296023?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.